MedPath

18F-FDG PET-MRI in patients with uterine cervical cancer - PETRA-C

Completed
Conditions
uterine cervical cancer
10038594
Registration Number
NL-OMON41355
Lead Sponsor
Academisch Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

Patients > 18 years
Inoperable cervical cancer, FIGO stage IIb or higher, based on the investigation under anaesthesia
Treatment plan: (chemo) radiation with curative intent
Informed consent

Exclusion Criteria

Tumor relapse
Conisation or lymph node dissection in the past
Claustrophobia, pregnancy, fasting serum blood sugar >10mmol/l, morbid obesity, standard MRI contraindications and joint prosthesis (as possible cause of attenuation artefacts on PET-CT or PET-MRI)

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>1. Practical aspects of 18F-FDG PET-MRI protocol (e.g. imbedding of our current<br /><br>MRI protocol in the PET-MRI protocol, presence of artifacts, optimal patient<br /><br>preparation)<br /><br>2. Assessment of the primary tumor: size and FDG uptake on 18F-FDG PET-MRI<br /><br>versus 18F-FDG PET-CT)<br /><br>3. Lymph node visualisation on 18F-FDG PET-MRI versus 18F-FDG PET-CT (pelvic<br /><br>and paraaortal)<br /><br>4. Patient comfort during 18F-FDG PET-MRI versus 18F-FDG PET-CT<br /><br>5. Detection of distant metastases<br /><br>6. The possibilities of PET-MRI based radiation treatment planning in a PET-MRI<br /><br>system not specially equipped with radiotherapy treatment facilities will be<br /><br>explored.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>n.a.</p><br>
© Copyright 2025. All Rights Reserved by MedPath